文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

HIV-1一线治疗失败者耐药突变率及决定因素的区域差异:D2EFT 3b/4期试验子研究

Regional Variations of Rates and Determinants of Drug Resistance Mutations in People Failing First-line Therapy for HIV-1: A Substudy from the D2EFT Phase 3b/4 Clinical Trial.
PubMed 文献 · Clin Infect Dis · 2026-01-01

D2EFT试验子研究分析了14个国家826名一线治疗失败者中727条序列的耐药突变,发现对拉米夫定/恩曲他滨(88.3%)和依非韦伦/奈韦拉平(92.8%/96.8%)的高水平耐药率极高,M184V/I达86.2%、K103N达57.8%,且突变分布存在区域差异。

要点

  • 一线治疗失败者中对拉米夫定、恩曲他滨、依非韦伦和奈韦拉平的高水平耐药率极高。
  • M184V/I是最常见的核苷类逆转录酶抑制剂突变,K103N是最常见的非核苷类突变。
  • K103N在非洲和南美洲国家更常见,既往齐多夫定暴露与T215F/Y相关。

核心结论

  • HIV-1耐药突变具有区域特异性,凸显了监测和了解当地突变谱的重要性。

研究设计与样本

  • D2EFT是一项3b/4期随机临床试验,本子研究分析一线治疗失败者 randomization 前的耐药突变分布,共纳入14个国家826名参与者中的727条序列。

主要发现

  • HIV-1 C亚型占59.3%。
  • 对拉米夫定和恩曲他滨的高水平耐药率均为88.3%,对依非韦伦和奈韦拉平分别为92.8%和96.8%。
  • M184V/I在86.2%的样本中检出,K103N在57.8%的样本中检出。
  • K103N在非洲和南美洲国家 occurrence 可能性增加(P < .05)。

临床怎么用

  • 在制定二线治疗方案前,应考虑当地耐药突变谱和既往抗逆转录病毒药物暴露史。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: D²EFT (Dolutegravir and Darunavir Evaluation in Adults Failing Therapy) was a phase 3b/4 randomized clinical trial designed to assess second-line treatment options systematically. This substudy evaluated the distribution of drug resistance mutations (DRMs) before treatment randomization in individuals failing first-line therapy. METHODS: From a total of 826 participants across 14 countries, 727 sequences that covered the PR-RT-INT (700), PR-RT (24), and RT (3) regions were analyzed for drug resistance. Sequences were submitted to the Stanford HIV drug resistance database to detect DRMs and assign subtypes. By adjusting for country and antiretroviral therapy regimen, we assessed the association between DRMs and country and reported DRMs. RESULTS: Subtype C of human immunodeficiency virus type 1 (HIV-1) accounted for most (59.3%) infections. There were extraordinarily high rates of high-level resistance to lamivudine and emtricitabine (both at 88.3%) and for efavirenz and nevirapine (92.8% and 96.8%, respectively). On average, nucleoside reverse transcriptase inhibitor mutations had the highest occurrence across countries with M184V/I detected in 86.2% of the samples, while the highest proportion of nonnucleoside reverse transcriptase inhibitor mutations was K103N at 57.8%. K103N had an increased likelihood of occurrence in African and South American countries (P < .05). Participants with prior exposure to a zidovudine-containing regimen had an increased likelihood of T215F/Y mutations (6.80 [2.59-17.86]), while those with nevirapine/rilpivirine exposure had a decreased likelihood of K103N mutations (0.29 [0.15-0.56]). CONCLUSIONS: The regional specificity of mutations underscores the dynamic nature of HIV-1 drug resistance patterns and the importance of monitoring and understanding local mutation profiles.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Obeng BM, Hutchinson J, Shaik A, et al. Regional Variations of Rates and Determinants of Drug Resistance Mutations in People Failing First-line Therapy for HIV-1: A Substudy from the D2EFT Phase 3b/4 Clinical Trial. Clin Infect Dis. 2026. PMID: 41482685. doi:10.1093/cid/ciaf739

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。